Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients

Pediatric Nephrology

Volumn 19, Issue 4, 2004, Pages 365-368

  Köpf, Sabine ^a   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Epstein Barr virus; Pediatric renal transplantation; Post transplant lymphoproliferative disorder

Indexed keywords

B LYMPHOCYTE ANTIBODY; CYCLOSPORIN; IBRITUMOMAB TIUXETAN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TOSITUMOMAB;

ACUTE GRAFT REJECTION; B LYMPHOCYTE; CANCER TISSUE; CELL PROLIFERATION; DRUG EFFICACY; EDITORIAL; EPSTEIN BARR VIRUS; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFECTIOUS MONONUCLEOSIS; KIDNEY TRANSPLANTATION; LEUKEMOGENESIS; LYMPHOCYTE FUNCTION; LYMPHOID CELL; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RISK FACTOR; STANDARDIZATION; T LYMPHOCYTE; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION;

ANIMALS; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MASS SCREENING; RISK FACTORS; VIRAL LOAD;

EID: 1842688665     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-004-1412-5     Document Type: Editorial

References (26)

1. Shroff R, Rees L (2004) The post-transplant lymphoproliferative disorder - a literature review. Pediatr Nephrol (http:// dx.doi.org/10.1007/s00467-003-1392-x)
2. Nalesnik MA (1996) Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 8:139-148
3. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS (1999) Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68:1517-1525
4. Harris NL, Ferry JA, Swerdlow SH (1997) Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 14:8-14
5. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
6. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361-1392
7. Köpf S, Tönshoff B (2004) Adenotonsillar hypertrophy and post-transplant lymphoproliferative disorder in pediatric renal transplant recipients. Pediatr Nephrol (http://dx.doi.org/10.1007/s00467-004-1413-4)
8. Cohen JI (2000) Epstein-Barr virus infection. N Engl J Med 343:481-492
9. Nalesnik MA (1996) Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 8:139-148
10. Nalesnik MA, Makowka L, Starzl TE (1988) The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 25:367-472
11. Riddler SA, Breinig MC, McKnight JL (1994) Increased levels of circulating Epstein-Baff virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 84:972-984
12. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C (1994) Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 83:2715-2722
13. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-13
14. Kenagy DN, Schlesinger Y, Week K, Ritter JH, Gaudreault-Keener MM, Storch GA (1995) Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 60:547-554
15. Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA, Lee CH, Emanuel DJ (1998) Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 91:3654-3661
16. McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martin MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW, Lee GS (1998) Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 66:1604-1611
17. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE (1995) Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 89:98-103
18. Green M, Bueno J, Rowe D, Mazariegos G, Qu L, Abu-Almagd K, Reyes J (2000) Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 70:593-596
19. Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, Sokal EM (2002) Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73:1603-1610
20. Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, Piantadosi S, Caligiuri MA, Ambinder RF (2000) Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 96:4055-4063
21. Muti G, Klersy C, Baldanti F, Granata S, Oreste P, Pezzetti L, Gatti M, Gargantini L, Caramella M, Mancini V, Gerna G, Morra E, Co-operative Study Group on PTLDs (2003) Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Br J Haematol 122:927-933
22. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW Jr, Hardesty RL et al (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet I:583-587
23. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, Schuster SJ, Porter DL, Montone KT, Stadtmauer EA (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71:1076-1088
24. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, Gandjbakhch I, Binet JL, Raphael M (1998) Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 16:2052-2059
25. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH (2000) Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 24:375-385
26. Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P, Garnier JL, Le Bidois J, Le Deist F, Blanche S, Fischer A (1998) Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 92:3137-3147